Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter a licensing agreement with Russia’s Lancet Pharmaceuticals, granting the latter regulatory filing, commercialization, and other rights for Buchang’s pipeline candidate BC001 across the Eurasian Economic Union, which includes Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan, and Uzbekistan.
Lancet will provide an undisclosed upfront payment to Buchang, along with commitments for milestone payments and royalties on future sales. BC001 is a Category 1 monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2), currently in development for the treatment of gastric cancer, non-small cell lung cancer (NSCLC), and other solid tumors. The candidate is undergoing a Phase III study as a second-line treatment in combination with paclitaxel for gastric and gastroesophageal junction adenocarcinoma. Additionally, it has received clinical trial approval for use in combination with a PD-1 inhibitor in advanced or metastatic solid tumors. Buchang aims to compete in the market dominated by Eli Lilly’s Cyramza (ramucirumab), which is approved for several advanced cancers.- Flcube.com
